Biochemistry of amyloid β-protein and amyloid deposits in Alzheimer disease

Topic: Disease mechanisms in lab and animal studies

Progressive cerebral deposition of the amyloid β-protein (Aβ) in brain regions serving memory and cognition is an invariant and defining feature of Alzheimer disease. A highly similar but less robust process accompanies brain aging in many nondemented humans, lower primates, and some other mammals. The discovery of Aβ as the subunit of the amyloid fibrils in meningocerebral blood vessels and parenchymal plaques has led to innumerable studies of its biochemistry and potential cytotoxic properties. Here we will review the discovery of Aβ, numerous aspects of its complex biochemistry, and current attempts to understand how a range of Aβ assemblies, including soluble oligomers and insoluble fibrils, may precipitate and promote neuronal and glial alterations that underlie the development of dementia. Although the role of Aβ as a key molecular factor in the etiology of Alzheimer disease remains controversial, clinical trials of amyloid-lowering agents, reviewed elsewhere in this book, are poised to resolve the question of its pathogenic primacy.

Key findings

• Progressive cerebral deposition of the amyloid β-protein (Aβ) in brain regions serving memory and cognition is an invariant and defining feature of Alzheimer disease.
• A highly similar but less robust process accompanies brain aging in many nondemented humans, lower primates, and some other mammals.
• The discovery of Aβ as the subunit of the amyloid fibrils in meningocerebral blood vessels and parenchymal plaques has led to innumerable studies of its biochemistry and potential cytotoxic properties.
• Here we will review the discovery of Aβ, numerous aspects of its complex biochemistry, and current attempts to understand how a range of Aβ assemblies, including soluble oligomers and insoluble fibrils, may precipitate and promote neuronal and glial alterations that underlie the development of dementia.
• Although the role of Aβ as a key molecular factor in the etiology of Alzheimer disease remains controversial, clinical trials of amyloid-lowering agents, reviewed elsewhere in this book, are poised to resolve the question of its pathogenic primacy.

New to this subject? Start with our plain-English guide: Treatments →

Study details

• Evidence strengthLow

Read the original

• DOI: 10.1101/cshperspect.a006262
• PubMed: 22675658
• Original source →

Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.

@article{masters2012-22675658,
  author  = {Masters, C. L. and Selkoe, D. J.},
  title   = {{Biochemistry of amyloid β-protein and amyloid deposits in Alzheimer disease}},
  journal = {Cold Spring Harbor perspectives in medicine},
  year    = {2012},
  doi     = {10.1101/cshperspect.a006262},
  pmid    = {22675658},
  url     = {https://doi.org/10.1101/cshperspect.a006262}
}

Related studies in Treatments

• Immunochemical identification of the serine protease inhibitor alpha 1-antichymotrypsin in the brain amyloid deposits of Alzheimer's disease Cell · 1988-02-01 · usefulness score 36/100
• Mapping post-translational modifications across amyloid-β deposits in Alzheimer’s disease: A neuropathologic survey with in vitro functional analysis of nitration Research Square · 2026-10-18 · usefulness score 16/100
• Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial Archives of neurology · 2003-12-01 · usefulness score 72/100
• A plasma protein signature for cerebral amyloid angiopathy Acta Neuropathologica · 2026-05-20 · usefulness score 51/100
• Glutamate system, amyloid ß peptides and tau protein: functional interrelationships and relevance to Alzheimer disease pathology Journal of psychiatry & neuroscience : JPN · 2013-01-01 · usefulness score 36/100
• Long-term Benefits and Harms Associated With Genetic Cholesteryl Ester Transfer Protein Deficiency in the General Population JAMA cardiology · 2022-01-01 · usefulness score 55/100

Similar studies

• Amyloid toxicity in Alzheimer's disease 2018 · End-of-life care
• Amyloid beta: structure, biology and structure-based therapeutic development 2017 · Risk genes beyond APOE
• The aqueous phase of Alzheimer's disease brain contains assemblies built from ∼4 and ∼7 kDa Aβ species 2015 · Biomarkers
• beta-Amyloid-(1-42) is a major component of cerebrovascular amyloid deposits: implications for the pathology of Alzheimer disease 1993 · Vascular contributions
• A beta oligomers - a decade of discovery 2007 · Risk genes beyond APOE
• Amyloid beta-protein deposition in tissues other than brain in Alzheimer's disease 1989 · Down syndrome and Alzheimer's

More on Treatments

• A review that covers this ground Peptide-Based Molecular Strategies To Interfere with Protein Misfolding, Aggregation, and Cell Degeneration Angewandte Chemie (International ed. in English) · 2019-11-28 · usefulness score 41/100
• Newest in this subject Opposing Regulation of Tau Condensation by Phosphorylation Levels and Molecular Chaperone Interactions bioRxiv · 2026-10-30 · Preprint — not yet peer-reviewed · usefulness score 16/100
• Newest in this subject Natural Sesquiterpenoids from Laggera pterodonta as bioactive Acetylcholinesterase Inhibitors: Insights from DFT, Molecular Docking, and ADMET Profiling Research Square · 2026-10-20 · Preprint — not yet peer-reviewed · usefulness score 16/100

See all studies in Treatments →